Relay Therapeutics: Breakthrough Designation Sets The Stage For A Key Zovegalisib Data Catalyst

Relay Therapeutics is approaching a pivotal clinical catalyst with the zovegalisib Phase 1/2 data readout at ESMO TAT. Check ...

Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million

Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational ...

Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones

Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026Breast cancer triplet data ...

Relay Therapeutics earnings in spotlight after FDA breakthrough

Relay Therapeutics Inc. reports fourth-quarter and full-year 2025 results Thursday after the market close, with investors eager to assess the clinical-stage biotech’s cash position and pipeline ...
The Herald News

Biomed Industries Announces Phase 3 Trials of NA-931 Targeting Durable Weight Loss & Lean-Mass Preservation at JPM Week

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation at JP Morgan Week 2026 Advancing NA-931, the first oral quadruple receptor ...
AOL

New weight loss drug by Pfizer shows promising results in trial

The pharmaceutical corporation Pfizer announced Tuesday that its experimental weight loss jab showed solid results when taken monthly during an ongoing mid-stage clinical trial. And there was no ...
Gizmodo

Pfizer’s Experimental Weight Loss Drug Shows Promise as a Once-a-Month Shot

In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a placebo. Reading time 2 minutes The competition to develop the next ...